1st Qtrly 16-17 2nd Qtrly 16-17 3rd Qtrly 16-17 4th Qtrly 16-17 30TH ANNUAL REPORT 2015-2016
1st Qtrly 15-16 2nd Qtrly 15-16 3rd Qtrly 15-16 4th Qtrly 15-16 29TH ANNUAL REPORT 2014-2015
1st Qtrly 14-15 2nd Qtrly 14-15 3rd Qtrly 14-15 4th Qtrly 14-15 28TH ANNUAL REPORT 2013-2014
1st Qtrly 13-14 2nd Qtrly 13-14 3rd Qtrly 13-14 4th Qtrly 13-14 27TH ANNUAL REPORT 2012-2013
1st Qtrly 12-13 2nd Qtrly 12-13 3rd Qtrly 12-13 4th Qtrly 12-13 26TH ANNUAL REPORT 2011-2012
1st Qtrly 11-12 2nd Qtrly 11-12 3rd Qtrly 11-12 4th Qtrly 11-12 25TH ANNUAL REPORT 2010-2011

COLINZ LABORATORIES LIMITED

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED

[  31st DECEMBER, 2011 ]

[ Rupees in ‘000]

 

 

Un-audited

Audited

Sr.
No.

Particulars

Quarter ended

Quarter ended

9 Months
Ended

9 Months
Ended

Year Ended

 

 

31.12.2011 31.12.2010 31.12.2011 31.12.2010 31.03.2011

1.

Net Sales

1,74,96

1,51,83

5,72,30

4,94,98

6,03,36

2.

Other Income

55

24

2,09

1,77

2,22

3.

Total Income

1,75,51

1,52,07

5,74,39

4,96,75

6,05,58

4.

Total Expenditure

 

 

 

 

 

 

(a)

Increase/ Decrease in Stock in Trade

14,73

-14,28

39,26

-1,78

-23,11

 

(b)

Consumption of Materials

50,70

63,91

2,01,77

2,03,25

2,40,79

 

(c)

Excise Duty

10,00

8,27

29,26

21,56

33,13

 

(d)

Staff Cost

49,42

40,38

1,39,28

1,16,41

1,50,94

 

(e)

Other Expenditure

37,00

40,49

1,24,23

1,20,59

1,54,60

5.

Profit before Interest,
Depreciation and Taxation

13,66

13,30

40,59

36,72

49,23

6.

Interest

5,26

4,46

13,24

11,66

15,61

7.

Depreciation

6,44

6,43

19,33

19,28

25,77

8.

Profit Before Tax

1,96

2,41

8,02

5,78

7,85

9.

Provision for  Current Tax

-

-

-

-

1,34

10.

Provision for Deferred Tax

-

-

-

-

(78)

11.

Fringe Benefit Tax

-

-

-

-

-

12.

Net Profit after Tax

1,96

2,41

8,02

5,78

7,29

13.

Paid up Equity Share Capital
[Net of allotment money in arrears]

3,54,35

3,54,35

3,54,35

3,54,35

3,54,35

14.

Reserves Excluding Revaluation Reserves  Less Deferred Tax  Provision.

-

-

-

-

65,26

15.

E. P. S.

-

-

-

-

0.16

16.

Aggregate of non promoter share -holding.
No. of shares
Percentages of shareholding

 30,80,150

 

67.38%

29,02,900

 

63.51%

30,80,150

 

67.38%

29,02,900

 

63.51%

29,02,900

 

63.51%

17.

Promoters and promoter group
Shareholding
a) Pledged/Encumbered
- Number of shares

 

 

-

 

 

-

 

 

-

 

 

-

 

 

-

 

- Percentage of shares (as a % of
the total shareholding of promoter and promoter group)

 

-

 

-

 

-

 

-

 

-

 

- Percentage of shares (as a% of
the total share capital of the
company)

 

-

 

-

 

-

 

-

 

-

 

b) Non-encumbered
- Number of Shares

 14,90,850

16,68,100

14,90,850

16,68,100

 16,68,100

 

- Percentage of shares (as a% of
the total shareholding of promoter and promoter group)

 100%

100%

 100%

100%

 100%

 

- Percentage of shares (as a % of
the total share capital of the
company)

 32.62%

36.49%

 32.62%

36.49%

 36.49%

 

STATEMENT OF ASSETS AND LIABILITES

 

As on 31.12.2011
(Reviewed)

As on 31.12.2010
( Reviewed)

CAPITAL & LIABILITIES

Capital
Reserve and Surplus
Secured Loan
Other Liabilities

 

3,54,35
2,98,50
94,59
1,53,83

 

3,54,35
2,82,57
1,03,84
1,60,48

Total
9,01,27
9,01,24

ASSETS

Investment
Fixed Assets
Net Current Assets

 

31,59
4,31,95
4,37,73

 

30,10
4,47,80
4,23,34

Total
9,01,27
9,01,24

 

NOTES :-

  1. The above results subjected to ‘Limited Review’ by the Auditors of the Company, were taken on record by the Board of Directors of the Company, at their meeting held on   
    31-01-2012
  2. The Un-audited results for the quarter do not reflect the trend for the year.
  3. Income Tax provision, whatever found necessary, will be considered at the end of the year
  4. The company operates in single segment of manufacture of pharmaceutical formulations. Hence Accounting Standard on segment reporting is not applicable
  5. The Company did not have any investors’ complaint pending at the beginning of the quarter. No investors’ complaints were received during the quarter and hence no investors’ complaints remained unsolved at the end of the quarter ended 31-12-2011.

 

  For and on behalf of the Board
  COLINZ LABORATORIES LIMITED
   
Mumbai Dr. L. S. Mani
31.01.2012 Chairman & Managing Director.

 

(Top)

Contact:
A/101, Pratik Estate,
Mulund Link Road,
Next to Fortis Hospital,
Mumbai-400078.
Tel.: 91-22-25668002/3
Fax: 91-22-25668006.
Email: cllfindoc@yahoo.com
Website:www.findoc-cll.in
Email:info@findoc-cll.in